Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30449151 | 1.00 | MAPK1 (0.43) | MAPK1PARP1CD274KDM4EL3MBTL1 | |
| SCHEMBL25720163 | 0.91 | MAPK1 (0.50) | MAPK1PARP1CD274KDM4EL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL31337868 | 0.81 | HDAC1 (0.47) | MEN1KMT2ARAB9A | |
| SCHEMBL21088880 | 0.79 | EPHX2 (0.39) | MAPK1PARP1CD274MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL25206585 | 0.76 | EPHX2 (0.40) | KDM4EMEN1KMT2ARAB9ASLC2A1 | |
| SCHEMBL21088781 | 0.76 | P4HTM (0.50) | MAPK1CD274KDM4EL3MBTL1MEN1 | |
| Trifluoroacetic Acid SCHEMBL25253303 | 0.75 | MEN1 (0.48) | KDM4EMEN1KMT2ABCHEACHE | |
| SCHEMBL2644039 | 0.75 | VNN1 (0.53) | KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL1584750 | 0.74 | MAPK1 (0.54) | MAPK1PARP1KDM4EL3MBTL1MEN1 | |
| SCHEMBL16417282 | 0.72 | MAPK1 (0.59) | MAPK1PARP1KDM4EL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | MAPK1 4583/4885PARP1 989/4885CD274 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.